Last month, the American Medical Association (AMA) announced that it is supporting value-based pricing for medications. The AMA supports initiatives “aimed at changing the fundamentals of prescription drug pricing without compromising patient outcomes and access.” The association also “seeks to blunt growing pharmaceutical spending rates by tying drug prices to an optimal balance of benefits and costs
In the article by Galdo and colleagues, “Comparing Community Pharmacy Quality Ratings Scores Among Data Analytics Companies” (Inside Patient Care, October 2016), the authors say, “Often, third-party companies calculate the value of the metrics for a community pharmacy, despite the quality metrics designed by the Pharmacy Quality Alliance (PQA) for health plan assessment.” This statement is correct, although taken out of context. My following comments intend to clarify some general information.

Results 1 - 2 of 2
  • American Health & Drug Benefits
  • The Journal of Hematology Oncology Pharmacy
  • Lynx CME
  • The Oncology Pharmacist